The effect of mesenchymal stromal cells of various origins on mortality and neurologic deficit in acute cerebral ischemia-reperfusion in rats

Home/2021, Vol. 9, No. 2/The effect of mesenchymal stromal cells of various origins on mortality and neurologic deficit in acute cerebral ischemia-reperfusion in rats

Cell and Organ Transplantology. 2021; 9(2):in press.
DOI: 10.22494/cot.v9i2.132

The effect of mesenchymal stromal cells of various origins on mortality and neurologic deficit in acute cerebral ischemia-reperfusion in rats

Konovalov S.1, Moroz V.1, Konovalova N.1, Deryabina O.2,3, Shuvalova N.2, Toporova O.2,3, Tochylovsky A.4, Kordium V.2,3

  • 1National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • 2State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • 3Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • 4BioTexCom LLC, Kyiv, Ukraine

Abstract

Stroke is a global epidemic issue and the second leading cause of death in the world and in Ukraine. According to official statistics, every year 100-110 thousand Ukrainians suffer acute cerebrovascular disorders. One third of such patients are of working age, up to 50 % will have a disability, and only one in ten will fully return to full life. So far, promising experimental data on the treatment of neurological dysfunction using mesenchymal stromal cells (MSCs) have been obtained.
The aim of study is to compare the effect of MSCs of different origins on mortality and neurologic deficit in rats with acute cerebral ischemia-reperfusion injury (CIRI).
Materials and methods. Acute cerebral ischemia-reperfusion was modeled by transient bilateral 20-minute occlusion of internal carotid arteries was modeled in male Wistar rats aged 4 months and animals were injected intravenously with 1·106 MSCs derived from human umbilical cord Wharton’s-jelly (hWJ-MSC), human and rat adipose tissue. Other groups of experimental animals were injected intravenously with rat fetal fibroblasts and cell lysate from hWJ-MSC. The last group of rats received Citicoline at a dose of 250 mg/kg as a reference drug. Control animals were injected intravenously with normal saline. The cerebroprotective effect of therapy was assessed by mortality and neurologic deficit in rats on the McGraw’s stroke index score.
Results. After 12 hours of observation in the crucial period in the development of experimental acute cerebrovascular disorders with the administration of hWJ-MSC, mortality was only 10 % against 45 % of animals in the control group. The use of rat fetal fibroblasts reduced the mortality of animals compare to the control group by an average of 25 %. CIRI in rats caused severe neurologic deficits: paralysis, paresis, ptosis, circling behavior. On the 7th day of observation in the control group of animals, the mean score on the McGrow’s stroke index indicated severe neurological disorders. On the 14th day of observation in this group of animals there was no complete recovery of lost central nervous system functions. Compared with the control group of animals, all the treatment agents for acute CIRI (MSCs of various origins, MSC’s lysate and Citicoline) contributed to a significant regression of neurologic deficit.
Conclusions. Thus, transplantation of human Wharton’s jelly-derived MSCs and rat fetal fibroblasts reduced mortality and alleviated neurological symptoms in rats with experimental ischemic stroke. hWJ-MSC, rat fetal fibroblasts, and rat adipose-derived MSCs reduced the incidence of neurological disorders better than Citicoline, which was accompanied by a regression of neurologic deficit dynamics on the 14th day of follow-up. The ability of stem cells of different origins to reduce neurologic deficit indicates the feasibility of their use in experimental acute cerebral ischemia.

Key words: ischemic stroke; cerebral ischemia-reperfusion injury, mesenchymal stromal cells; mortality; neurologic deficit

 

1. Available from: https://www.world-stroke.org/world-stroke-day-campaign/why-stroke-matters/learn-about-stroke
2. Available from: https://phc.org.ua/news/29-zhovtnya-vsesvitniy-den-borotbi-z-insultom, центр громадського здоров’я
3. Available from: https://www.kmu.gov.ua/news/stacionarne-likuvannya-gostrogo-mozkovogo-insultu-shcho-zminitsya-u-programi-medichnih-garantij-2021
4. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018; 378:708-718. DOI: 10.1056/NEJMoa1713973
https://doi.org/10.1056/NEJMoa1713973
PMid:29364767 PMCid:PMC6590673
5. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378:11-21. DOI: 10.1056/NEJMoa1706442
https://doi.org/10.1056/NEJMoa1706442
PMid:29129157
6. Cheng T, Yang B, Li D, et al. Wharton’s Jelly transplantation improves neurologic function in a rat model of traumatic brain injury. Cell Mol Neurobiol. 2015; 35:641-9.
https://doi.org/10.1007/s10571-015-0159-9
PMid:25638565 PMCid:PMC4481175
7. Donders R, Bogie JFJ, Ravanidis S, et al. Human Wharton’s Jelly-derived stem cells display a distinct immunomodulatory and proregenerative transcriptional signature compared to bone marrow-derived stem cells. Stem Cells Dev 2018; 27:65-84.
https://doi.org/10.1089/scd.2017.0029
PMid:29267140
8. He JQ, Sussman ES, Steinberg GK. Revisiting Stem Cell-Based Clinical Trials for Ischemic Stroke. Front Aging Neurosci. 2020; 12:575990. DOI: 10.3389/fnagi.2020.575990
https://doi.org/10.3389/fnagi.2020.575990
PMid:33381020 PMCid:PMC7767918
9. Wu KJ, Yu SJ, Chiang CW, et al. Neuroprotective action of human wharton’s jelly-derived mesenchymal stromal cell transplants in a rodent model of stroke. Cell Transplant. 2018; 27:1603-1612.
https://doi.org/10.1177/0963689718802754
PMid:30284460 PMCid:PMC6299196
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4):1815-1822. DOI:10.1182/blood-2004-04-1559
https://doi.org/10.1182/blood-2004-04-1559
PMid:15494428
11. Tondreau T, Meuleman N, Delforge A, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells. 2005; 23(8):1105-12. DOI: 10.1634/stemcells.2004-0330
https://doi.org/10.1634/stemcells.2004-0330
PMid:15955825
12. Zhang L, Wang LM, Chen WW, et al. Neural differentiation of human Wharton’s jelly-derived mesenchymal stem cells improves the recovery of neurological function after transplantation in ischemic stroke rats. Neural Regen Res. 2017; 12:1103-1110.
https://doi.org/10.4103/1673-5374.211189
PMid:28852392 PMCid:PMC5558489
13. Khodakovskij AA, Marinich LI, Bagauri OV. Features of the formation of post-reperfusion damage to neurons – a characteristic of the “ischemia-reperfusion” model. New directions and prospects for the development of modern cerebroprotective therapy for ischemic stroke. Doctor-graduate student. 2013; 3(58):69-76. [In Russian]
14. Tsymbaliuk VI, Deryabina OG, Shuvalova NS, Maslova OO, Pokholenko IaO, Toporova OK, et al. Phenotypical changes and proliferative potential of mesenchymal stem cells from humans Wharton’s jelly in the cultivation conditions. Ukr Neurosurg J. 2015; 2:17-24.
https://doi.org/10.25305/unj.45290
15. Estes BT, Diekman BO, Gimble JM, Guilak F. Isolation of adipose derived stem cells and their induction to a chondrogenic phenotype. Nat Protoc. 2010; 5(7):1294-1311. DOI:10.1038/nprot.2010.81
https://doi.org/10.1038/nprot.2010.81
PMid:20595958 PMCid:PMC3219531
16. Kurzyk A, Dębski T, Święszkowski W, Pojda Z. Comparison of adipose stem cells sources from various locations of rat body for their application for seeding on polymer scaffolds. J Biomater Sci Polym Ed. 2019; 30(5):376-397. Available from: https://doi.org/10.1080/09205063.2019.1570433
https://doi.org/10.1080/09205063.2019.1570433
PMid:30686126
17. Weber SC, Gratop A, Akanbi S, Rheinlaender C, Sallmon H, Barikbin B, et al. Isolation and culture of fibroblasts, vascular smooth muscle, and endothelial cells from the fetal rat ductus arteriosus. Pediatr Res. 2011; 70(3):236-41. DOI: 10.1203/PDR.0b013e318225f748
https://doi.org/10.1203/PDR.0b013e318225f748
PMid:21629157
18. Diederich K, Frauenknecht K, Minnerup J, et al. Citicoline enhances neuroregenerative processes after experimental stroke in rats [published correction appears in Stroke. 2012; 43(11):e169]. Stroke. 2012; 43(7):1931-1940. DOI:10.1161/STROKEAHA.112.654806
https://doi.org/10.1161/STROKEAHA.112.654806
PMid:22581817
19. Bustamante A, Giralt D, Garcia-Bonilla L, et al. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem. 2012; 123(2):217-225.
https://doi.org/10.1111/j.1471-4159.2012.07891.x
PMid:22845688
20. Mehta A, Mahale R, Buddaraju K, et al. Efficacy of Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful? Journal of neurosciences in rural practice. 2019; 10(4):576-581.
https://doi.org/10.1055/s-0039-1700790
PMid:31831974 PMCid:PMC6906097
21. McGraw CP, Pashayan AG, Wendel OT. Cerebral infarction in the Mongolian gerbil exacerbated by phenoxybenzamine treatment. Stroke. 1976; 7(5):485-488.
https://doi.org/10.1161/01.STR.7.5.485
PMid:785717
22. Lee MC, Jin CY, Kim HS, et al. Stem cell dynamics in an experimental model of stroke. Chonnam Med J. 2011; 47(2):90-98. DOI.org/10.4068/cmj.2011.47.2.90
https://doi.org/10.4068/cmj.2011.47.2.90
PMid:22111067 PMCid:PMC3214868
23. Ding DC, Shyu WC, Chiang MF, et al. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis. 2007; 27:339-53.
https://doi.org/10.1016/j.nbd.2007.06.010
PMid:17651977
24. Wu CJ, Wang ZY, Yang YX, Luan Z. Long-term effect of oligodendrocyte precursor cell transplantation on a rat model of white matter injury in the preterm infant. Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(9):1003-1007.
https://doi.org/10.7499/j.issn.1008-8830.2017.09.01
25. Toyoshima A, Yasuhara T, Kameda M, Morimoto J, Takeuchi H, Wang F. Intra-arterial transplantation of allogeneic mesenchymal stem cells mounts neuroprotective effects in a transient ischemic stroke model in rats: analyses of therapeutic time window and its mechanisms. PLoS One. 2015; 10:e0127302. DOI: 10.1371/journal.pone.0127302
https://doi.org/10.1371/journal.pone.0127302
PMid:26075717 PMCid:PMC4468176
26. Moisan A, Favre I, Rome C, De Fraipont F, Grillon E, Coquery N. Intravenous injection of clinical grade human MSCs after experimental stroke: functional benefit and microvascular effect. Cell Transplant. 2016; 25:2157-2171. DOI: 10.3727/096368916X691132
https://doi.org/10.3727/096368916X691132
PMid:26924704
27. Hu Y, Chen W, Wu L, Jiang L, Qin H, Tang N. Hypoxic preconditioning improves the survival and neural effects of transplanted mesenchymal stem cells via CXCL12/CXCR4 signalling in a rat model of cerebral infarction. Cell Biochem. Funct. 2019; 37:504-515. DOI: 10.1002/cbf.3423
https://doi.org/10.1002/cbf.3423
PMid:31368195
28. Son JW, Park J, Kim YE, Ha J, Park DW, Chang MS. Glia-like cells from late-passage human MSCs protect against ischemic stroke through IGFBP-4. Mol Neurobiol. 2019; 56:7617-7630. DOI: 10.1007/s12035-019-1629-8
https://doi.org/10.1007/s12035-019-1629-8
PMid:31081524

Konovalov S, Moroz V, Konovalova N, Deryabina O, Shuvalova N, Toporova O, Tochylovsky A, Kordium V. The effect of mesenchymal stromal cells of various origins on mortality and neurologic deficit in acute cerebral ischemia-reperfusion in rats. Cell Organ Transpl. 2021; 9(2):in press. doi:10.22494/cot.v9i2.132

Creative Commons License
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.